Showing results (191-200 of 1,842) with videos related to
Sort By:
Pageof 185
Journal of Managed Care & Specialty Pharmacy|March 31, 2024
Comparison of time to treatment initiation of specialty medications between an integrated health system specialty pharmacy and external specialty pharmaciesMegan Russell, Heather McCoy, Thom Platt, et al.Journal of Managed Care & Specialty Pharmacy|December 7, 2023
A primer on managed care pharmacyLaura E Happe, Babette S EdgarJournal of Managed Care & Specialty Pharmacy|December 7, 2023
HIV preexposure prophylaxis treatment patterns in a national health plan populationJeremiah Rastegar, Amy Hu, Linda Chung, et al.Journal of Managed Care & Specialty Pharmacy|December 6, 2023
Health care resource utilization and costs among patients with spasticity or cervical dystoniaMichael Hull, Natalya Danchenko, Vamshi Ruthwik Anupindi, et al.Journal of Managed Care & Specialty Pharmacy|July 22, 2024
Implications of treatment duration and frequency for value and cost-effective price of Alzheimer treatmentsSoeren Mattke, Tabasa Ozawa, Mark HansonJournal of Managed Care & Specialty Pharmacy|July 1, 2024
Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiativeE Danielle Bryan, Chelsea P Renfro, Rebekah H Anguiano, et al.Journal of Managed Care & Specialty Pharmacy|July 11, 2024
How adoption of new pharmaceuticals can impact US health system reimbursement under alternative payment models: An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetesJason Shafrin, Shanshan Wang, Jaehong Kim, et al.Journal of Managed Care & Specialty Pharmacy|June 2, 2024
Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-releaseJeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, et al.Journal of Managed Care & Specialty Pharmacy|June 4, 2024
Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schizophrenia or schizoaffective disorderCarmela Benson, Charmi Patel, Inyoung Lee, et al.Journal of Managed Care & Specialty Pharmacy|August 23, 2023
Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping reviewYue Yin, Cara McDermott, Catherine LockhartPageof 185